All posts by: Michael Zand

CRISPR has success in treating mice with type 1 diabetes – Diabetes.co.uk

BSA bureau (press release)CRISPR has success in treating mice with type 1 diabetesDiabetes.co.ukAmerican scientists adapted the gene editing technology known as CRISPR (clustered, regularly interspaced, short palindromic repeat) to successfully treat m… Continue reading

Synthetic Biology Market Growth Analysis to 2022 – Newsient – Newsient (blog)

Synthetic Biology Market Growth Analysis to 2022 – NewsientNewsient (blog)HTF MI published a new industry research that focuses on Synthetic Biology market and delivers in-depth market analysis and future prospects of Global Synthetic Biology market. … Continue reading

New CRISPR technique reverses diabetes and kidney failure in mice without cutting DNA – BioNews

BioScholar NewsNew CRISPR technique reverses diabetes and kidney failure in mice without cutting DNABioNewsScientists in California have used a modified form of the CRISPR/Cas9 genome editing approach to epigenetically treat diabetes, kidney disease an… Continue reading

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust … – Digital Journal

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust … Digital Journal CAMBRIDGE, Mass.–(Business Wire)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … and more »

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust … Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … and more »

Magenta Therapeutics’ Expanded Stem Cell Product, MGTA-456, Engrafts in 100% of Patients, Leading to Robust … Business Wire (press release) CAMBRIDGE, Mass.–(BUSINESS WIRE)–Magenta Therapeutics, a biotechnology company developing therapeutics to improve and extend the use of curative bone marrow transplant for more patients, today reported Phase 2 clinical data from its MGTA-456 … and more »

Immunotherapy Combo Effective Against Rare Non-Hodgkin Lymphoma Specialty Pharmacy Times AbbVie recently announced positive results from a phase 3 clinical trial investigating ibrutinib (Imbruvica) plus rituximab in patients with Waldenström’s macroglobulinemia (WM), a rare non-Hodgkin lymphoma. Only 1000 to 1500 patients are diagnosed …